The first biosmilar products have been approved in the U.S. and Canada, following Europe’s early lead. Canada approved its first biosimilar monoclonal antibody (mAb) therapy, known as Inflectra (infliximab), on March 30, 2015.1 In Canada, biosimilars are being called subsequent entry biologic (SEB) agents. Inflectra is approved for treating patients with rheumatoid arthritis (RA), ankylosing…
Biosimilar for Infliximab Launched in Europe
Plus, updates on arhalofenate, ALO-02, and other rheumatology drug news, safety information
Infliximab, Tocilizumab Can Help in Large Vessel Vasculitis
Case studies show some patients with LVV can achieve remission after treatment with biological agents
2014 ACR/ARHP Annual Meeting: Rheumatology Drug Updates, Safety News
Plus, hydrocodone combination products and brodalumab
Hepatitis Reaction with Rituximab Sparks Drug Safety Alert
The FDA modifies rituximab prescribing information to stress risk of hepatitis B virus reactivation
Vaccines and Biologics: What Rheumatologists Need to Know
How vaccines, medications and rheumatic disease-related effects on immune system interact
Atacicept, Mavrilimumab Drug Updates, Trials, Safety Data
Plus, rheumatology drug news, safety updates
EULAR 2014: Collaboration Among Rheumatology Groups Expected to Build
ACR, European League Against Rheumatism, other groups, to work together creating disease criteria and response sets, patient management guidelines
Vaccinations for Immunocompromised Patients Are Shared Responsibility of Specialists, Primary Care Physicians
Infectious Diseases Society of America recommends both physician groups educate patients, household members on importance of vaccines
Metabolic Syndrome Linked to Higher Risk for Immunological Disorders
Research suggests patients with metabolic disorders, such as diabetes, might benefit from antiinflammatory drugs used to treat immunlogical disorders
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 40
- Next Page »